Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2025-07-29 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-07-29 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Déclaration des transactions sur actions propres' (Declaration of transactions on own shares) and provides a detailed breakdown of share repurchase transactions conducted by Sanofi between July 21, 2025, and July 25, 2025. It includes tables showing daily aggregated volumes and individual transaction details, which is the standard format for reporting share buybacks under market abuse regulations (MAR). This fits the definition of 'Transaction in Own Shares' (POS).
2025-07-28 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and provides a detailed breakdown of share repurchases by Sanofi, including daily volumes, weighted average prices, and individual transaction logs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-07-28 English
Communiqué de presse : Sarclisa de Sanofi approuvé dans l’UE pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the European Commission's approval of the drug 'Sarclisa' for a specific medical condition (multiple myeloma). It details the clinical study results (GMMG-HD7) that led to this regulatory approval. As it is a corporate announcement regarding product development and regulatory status, it falls under the category of general regulatory announcements or corporate news, which is best classified as RNS (Regulatory Filings) in this taxonomy.
2025-07-25 French
Press Release: Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
Regulatory Filings Classification · 95% confidence The document is a press release from Sanofi announcing the European Commission's approval of their drug 'Sarclisa' for a specific medical condition. It details the clinical study results (GMMG-HD7) that led to this regulatory approval. This type of announcement, which focuses on product development, regulatory milestones, and clinical trial outcomes, is classified as a general regulatory announcement or corporate update. Since it does not fit into specific categories like financial reports, earnings releases, or shareholder voting, it falls under the 'Regulatory Filings' (RNS) category.
2025-07-25 English
6-K
Regulatory Filings
2025-07-22 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.